Loading...

PE anti-mouse CD4 Antibody

Pricing & Availability
Clone
RM4-4 (See other available formats)
Regulatory Status
RUO
Other Names
L3T4, T4
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
RM4-4_PE
C57BL/6 mouse splenocytes stained with CD3 (145-2C11) FITC and RM4-4 PE
  • RM4-4_PE
    C57BL/6 mouse splenocytes stained with CD3 (145-2C11) FITC and RM4-4 PE
Compare all formats See PE spectral data
Cat # Size Price Save
116005 50 µg ¥18,520
116006 200 µg ¥43,440
Description

CD4 is a 55 kD protein, also known as L3T4 or T4. It is a member of the Ig superfamily, primarily expressed on most thymocytes and a subset of T cells, and weakly on macrophages and dendritic cells. It acts as a coreceptor with the TCR during T cell activation and thymic differentiation by binding MHC class II and associating with the protein tyrosin kinase, lck.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
BALB/c mouse thymocytes
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

RM4-4 antibody does not block the binding of GK1.5 and RM4-5 antibodies to CD4 T cells. For immunohistochemistry applications, the RM4-5 (Cat. No. 100506) and GK1.5 (Cat. No. 100402) antibodies are recommended.

Application References

(PubMed link indicates BioLegend citation)
  1. Bendelac A. 1995. Curr. Opin. Immunol. 7:367.
  2. Norian LA and Allen PM. 2004. J. Immunol. 173:835.
Product Citations
  1. Quispe Calla N, et al. 2016. Sci Rep. 6:37723. PubMed
  2. Grigsby SM, et al. 2021. Cancers (Basel). 13:. PubMed
  3. Guo X, et al. 2022. Invest Ophthalmol Vis Sci. 63:12. PubMed
  4. Pinto NA, et al. 2023. Cell Death Differ. :. PubMed
  5. Lütge M, et al. 2023. Nat Immunol. . PubMed
  6. Schloss MJ, et al. 2022. Nat Immunol. 23:605. PubMed
  7. Kim D, et al. 2021. Nanomicro Lett. 13:31. PubMed
  8. Gern BH, et al. 2021. Cell Host Microbe. 29(4):594-606.e6. PubMed
  9. Song C, et al. 2019. Nat Commun. 10:3745. PubMed
  10. Saleh MM, et al. 2019. Cell Host Microbe. 25:756. PubMed
  11. Pradier L, et al. 2018. Alzheimers Res Ther. 0.497916667. PubMed
  12. Hsu SPC, et al. 2020. J Neurooncol. 146:417. PubMed
  13. Lee H, et al. 2020. Cell Metabolism. 31(4):822-836. PubMed
  14. Rodriguez-García A, et al. 2021. Nat Commun. 12:877. PubMed
  15. Waide ML, et al. 2020. Cell Rep. 33:108503. PubMed
  16. Rao E, et al. 2021. Sci Immunol. 6:. PubMed
  17. Vicetti Miguel R, et al. 2016. PLoS One. 11: 0162445. PubMed
  18. Roufaiel M, et al. 2016. Nat Immunol. 10.1038/ni.3564. PubMed
  19. Su W, et al. 2020. Cell Metabolism. 32(6):996-1011.e7. PubMed
  20. Bartleson JM, et al. 2020. Nat Immunol. 1384:21. PubMed
  21. Brooks JF, et al. 2020. Cytotherapy. 22:436. PubMed
  22. Papafragkos I, et al. 2022. Front Immunol. 13:889075. PubMed
  23. Guo W, et al. 2022. J Immunother Cancer. 10:. PubMed
  24. Xiao P, et al. 2019. J Exp Med. 216:337. PubMed
  25. Frazier T, et al. 2018. Adipocyte. 0.41875. PubMed
  26. Galvani S, et al. 2015. Sci Signal. 8: ra79. PubMed
  27. Garo LP, et al. 2019. Cell Rep. 28:3353. PubMed
  28. Horkova V, et al. 2020. Cell Reports. 30(5):1504-1514.e7.. PubMed
  29. Xiao L, et al. 2021. Clin Cancer Res. 27:4338. PubMed
  30. Moguche AO et al. 2017. Cell host & microbe. 21(6):695-706 . PubMed
  31. Hou Y, et al. 2021. Sci Transl Med. 13:. PubMed
  32. Mandal RK, et al. 2021. Cell Reports. 35(6):109094. PubMed
  33. Cai Z, et al. 2020. Cell Rep. 31:107816. PubMed
  34. Kalafati L, et al. 2020. Cell. 183:771. PubMed
  35. Baldwin LA, et al. 2022. Nat Commun. 13:6539. PubMed
  36. Wu Y, et al. 2015. J Immunol. 195: 2612-2623. PubMed
  37. Arensman MD, et al. 2020. Oncoimmunology. 9:1800162. PubMed
  38. Shi H et al. 2018. Immunity. 49(5):899-914 . PubMed
  39. Fasolino M, et al. 2020. Immunity. 257:52. PubMed
  40. Lalor R, et al. 2019. Nutrients. 11. PubMed
  41. Louise V Webb et al. 2019. Immunity. 50(2):348-361 . PubMed
  42. Johnson JL et al. 2018. Immunity. 48(2):243-257 . PubMed
RRID
AB_313690 (BioLegend Cat. No. 116005)
AB_313690 (BioLegend Cat. No. 116006)

Antigen Details

Structure
Ig superfamily, 55 kD
Distribution

Majority of thymocytes, T cell subset

Function
TCR co-receptor, T cell activation
Ligand/Receptor
MHC class II molecule
Cell Type
T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press. 
2. Bierer BE, et al. 1989. Annu. Rev. Immunol. 7:579. 
3. Janeway CA. 1992. Annu. Rev. Immunol. 10:645.

Gene ID
12504 View all products for this Gene ID
UniProt
View information about CD4 on UniProt.org

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.
TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.
What type of PE do you use in your conjugates?
We use R-PE in our conjugates.
Go To Top Version: 2    Revision Date: 01/02/2014

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account